Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Released on April 23, 2001 and published on-line by the AIDS Treatment Information Service.

Recent updates appear in red.

Summary
Introduction
Uses of Testing in Guiding Decisions for Therapy
Testing for Drug Resistance
Considerations for Patients with Established HIV Infection
Considerations for Initiating Therapy in the Patient with
    Asymptomatic HIV Infection
Considerations for Discontinuing Therapy
Adherence to Potent Antiretroviral Therapy
Goals of Therapy
Initiating Therapy in the Patient with Asymptomatic HIV Infection
Initiating Therapy in Advanced HIV Disease
HAART-Associated Adverse Clinical Events
Interruption of Antiretroviral Therapy
Considerations for Changing a Failing Regimen
Criteria for Changing Therapy
Therapeutic Options When Changing Antiretroviral Therapy
Acute HIV Infection
Considerations for Therapy in the HIV-Infected Adolescent
Considerations for Therapy in the HIV-Infected Pregnant Woman
Conclusion
References
Considerations for Antiretroviral Therapy in Women
Hydroxyurea
Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy
Antiretroviral Pregnancy Registry

Figure I. Likelihood of Developing AIDS Within 3 Years
Table I. Rating Scheme for Clinical Practice
Table II. Indications for Plasma HIV RNA Testing
Table III. Recommendations for the Use of Drug Resistance Assays
Table IV. Risks and Benefits of Delayed Initiation of Therapy and of
   Early Therapy in the Asymptomatic HIV-Infected Patient
Table V. Risk of Progression to AIDS Defining Illness in a Cohort of
   Homosexual men Predicted by Baseline CD4+ T Cell Count and Viral
   Load
Table VI. Indications for the Initiation of Antiretroviral Therapy in the
   Chronically HIV-1 Infected Patient
Table VII. Strategies to Improve Adherence: Patient and Medication-
   Related
Table VIII. Strategies to Improve Adherence: Clinician and Health
   Team-Related
Table IX. Interventions Associated with Improved Adherence
Table X. Goals of HIV Therapy and Tools to Achieve Them
Table XI. Advantages and Disadvantages of Class-Sparing Regimens
Table XII. Recommended Antiretroviral Agents for Initial Treatment of
   Established HIV Infection
Table XIII. Characteristics of Nucleoside Reverse Transcriptase
   Inhibitors (NRTIs)
Table XIV. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Table XV. Characteristics of Protease Inhibitors (PIs)
Table XVI. Drugs That Should Not Be Used With PI Antiretrovirals
Table XVII. Drug Interactions Between Antiretrovirals and Other Drugs
   Protease Inhibitors (PIs)
Table XVIII. Drug Interactions: Protease Inhibitors
   Effect of Drug on Levels (AUCs)/Dose
Table XIX. HIV-Related Drugs with Overlapping Toxicities
Table XX. Drugs Available Through Treatment Investigational
   New Drug Protocols
Table XXI. Guidelines for Changing an Antiretroviral Regimen for
   Suspected Drug Failure
Table XXII. Acute Retroviral Syndrome: Associated Signs and
   Symptoms (Expected Frequency) (ref. #159)
Table XXIII. Preclinical and Clinical Data Relevant to Use of
   Antiretrovirals in Pregnancy
Table XXIV. Zidovudine Perinatal Transmission Prophylaxis Regimen